Keywords: Viiv Healthcare, Pfizer, GlaxoSmithKline, Shionogi, Dolutegravir, HIV-1, Ph III

ViiV and Shionogi say dolutegravir meets primary endpoint in HIV

Article | 02 April 2012

Print This

ViiV Healthcare, the HIV/AIDS joint venture of UK drugs giant GlaxoSmithKline (LSE: GSK) and US behemoth Pfizer (NYSE: PFE), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in